Ozempic (semaglutide) is not recommended during pregnancy, and the FDA-approved prescribing information advises discontinuing it at least 2 months before a planned pregnancy. The washout period reflects semaglutide’s elimination half-life of approximately one week, which means roughly five weeks are required for 97% clearance, plus a deliberate safety margin. Animal reproduction studies showed embryo-fetal harm at clinically relevant exposures, and no adequate controlled human studies exist. If you discover you are pregnant while taking semaglutide, stop the medication and contact your clinician — published observational data have not established a consistent pattern of birth defects. Advanced TRT Clinic is not affiliated with or endorsed by Novo Nordisk (Ozempic, Wegovy).
Why Semaglutide Is Not Used During Pregnancy
Ozempic (semaglutide 0.5mg to 2mg) is FDA-approved for type 2 diabetes, for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease, and to slow progression of chronic kidney disease in type 2 diabetes. Pregnancy is not among its approved uses, and the label advises against use during pregnancy. The recommendation rests on three separate lines of reasoning, each of which stands on its own.
Animal reproduction data. In reproductive toxicity studies conducted in rats, rabbits, and cynomolgus monkeys, semaglutide exposure during organogenesis was associated with embryo-fetal mortality, structural abnormalities, and altered fetal growth. These effects occurred at maternal exposures at or below those reached at the maximum recommended human dose. Animal findings do not translate directly to humans, but in the absence of adequate human data they set the regulatory position.
Absence of controlled human trials. No adequate, well-controlled studies of semaglutide have been conducted in pregnant women, and none is likely to be. Randomizing pregnant patients to an agent with adverse animal reproduction findings would not be ethical. What exists instead is observational data from patients who conceived while taking a GLP-1 receptor agonist, drawn from registries and insurance claims cohorts.
Caloric restriction during a period of increased nutritional demand. This concern receives less attention than it deserves. Semaglutide works by reducing appetite and caloric intake. Pregnancy is a state of elevated nutritional requirement, and intentional weight loss during pregnancy is not recommended even for patients with obesity. A medication whose entire therapeutic mechanism is appetite suppression works against fetal nutritional needs, independent of any direct teratogenic effect.
Ozempic (semaglutide 0.5mg to 2mg) is FDA-approved for type 2 diabetes. Wegovy (semaglutide 2.4mg) is FDA-approved for weight management. The pregnancy guidance, the washout recommendation, and the breastfeeding precaution are identical across both products, because they contain the same molecule. Tirzepatide products (Mounjaro, Zepbound) carry comparable pregnancy precautions. Nothing in this article constitutes medical advice, and no GLP-1 receptor agonist should be started or stopped without physician oversight. Advanced TRT Clinic is not a pharmacy and does not sell or fulfill prescriptions.
The 2-Month Washout: Where the Number Comes From
The washout period is the interval between the final semaglutide injection and the point at which conception is considered acceptable. The FDA label specifies at least two months. The reasoning is pharmacokinetic rather than arbitrary, and it is worth understanding rather than simply following.
Semaglutide has an elimination half-life of approximately one week — unusually long for an injectable peptide, and precisely what allows once-weekly dosing. The practical consequence is slow clearance. After one half-life, half the drug remains. After five half-lives, approximately 97% has been eliminated. At one week per half-life, that is roughly five weeks to near-complete clearance.
The two-month recommendation adds a deliberate margin on top of those five weeks. It accounts for variation in clearance between individuals, for patients uncertain of their exact last-dose date, and for the reality that conception frequently occurs two to three weeks before a pregnancy test turns positive.
Semaglutide Clearance After the Final Injection (One-Week Half-Life)
| Time Since Last Dose | Half-Lives Elapsed | Approximate Drug Remaining | Status |
|---|---|---|---|
| Week 1 | 1 | 50% | Substantial exposure continues |
| Week 2 | 2 | 25% | Substantial exposure continues |
| Week 3 | 3 | 12.5% | Declining |
| Week 4 | 4 | 6.3% | Declining |
| Week 5 | 5 | ~3% | 97% cleared |
| Week 8 (2 months) | 8 | Under 1% | FDA label recommendation |
Figure 1. Theoretical first-order elimination at an approximate one-week half-life. Illustrative only — individual clearance varies, and discontinuation timing should be set by your prescribing clinician.
Because conception typically precedes a positive pregnancy test by two to three weeks, patients actively trying to conceive should complete the full washout before beginning to try — not before the month in which they hope to conceive. Working backward from a target conception date, the final injection should fall at least eight weeks earlier. Patients who are uncertain of their last-dose date should assume the earlier of the possible dates rather than the later.
What the Human Data Actually Show
Patients who conceive on a GLP-1 receptor agonist are understandably alarmed. The available human evidence is reassuring but incomplete, and it deserves to be described accurately rather than either minimized or overstated.
Several observational cohort studies have compared pregnancy outcomes in patients exposed to GLP-1 receptor agonists during the first trimester against patients with pre-existing diabetes treated with insulin or other agents. Published analyses to date have not identified a significant increase in the rate of major congenital malformations attributable to GLP-1 exposure.
Three limitations matter when interpreting these findings. Sample sizes remain modest relative to the low baseline incidence of specific birth defects, meaning rare outcomes could be missed. Confounding is difficult to eliminate, because maternal diabetes and obesity independently raise malformation risk and are the reason the medication was prescribed in the first place. And most published exposure data involve older agents such as liraglutide rather than semaglutide specifically.
Supported: the available human data do not demonstrate that first-trimester GLP-1 exposure causes birth defects.
Supported: unplanned exposure before pregnancy recognition is common and is not, by itself, a basis for considering pregnancy termination.
Not supported: continuing the medication once pregnancy is known.
Not supported: treating the observational data as definitive evidence of safety. Sample sizes are modest and most exposure data involve older GLP-1 agents.
The clinically appropriate response to unplanned exposure is to stop the medication, notify the obstetric provider so that standard anatomy screening can be arranged, and transition diabetes management to an agent with established pregnancy safety data.
If You Become Pregnant While Taking Semaglutide
Unplanned exposure is common enough that clinicians encounter it regularly. The response is straightforward, and acting on it quickly matters more than any single decision within it.
| Situation | Recommended Action | Timing |
|---|---|---|
| Positive pregnancy test while on semaglutide | Stop the medication. Do not take the next scheduled injection. Contact the prescribing clinician and obstetric provider. | Immediate |
| Type 2 diabetes requiring ongoing treatment | Transition to an agent with established pregnancy data — typically insulin, the standard of care for diabetes in pregnancy. Do not simply stop treating the diabetes. | Immediate |
| Uncertain whether you are pregnant | Test before the next scheduled injection rather than after. Weekly dosing makes this practical. | Same week |
| Planning pregnancy in the next 6 to 12 months | Agree a discontinuation plan with the prescribing clinician, allowing at least 8 weeks between the final dose and attempting conception. | Plan ahead |
| Washout complete, now trying to conceive | Proceed with standard preconception care: folic acid supplementation, glycemic optimization, full medication review. | Routine |
| Postpartum, considering restarting | Discuss timing with a clinician, accounting for breastfeeding status and current metabolic indication. | Routine |
What not to do
Do not taper. There is no pharmacologic benefit to a gradual dose reduction once pregnancy is confirmed, and tapering extends fetal exposure unnecessarily. Do not delay contacting the clinician out of concern about having made a mistake — exposure before pregnancy recognition is common and is not treated as a failure by any competent provider. And do not stop treating diabetes. Uncontrolled maternal hyperglycemia in the first trimester carries a well-documented risk of congenital malformation that substantially exceeds any established risk from GLP-1 exposure.
In rodent studies, semaglutide caused dose-dependent thyroid C-cell tumors. It is not known whether this risk applies to humans. Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). Other reported risks across the product labeling include pancreatitis, gallbladder disease, diabetic retinopathy complications in type 2 diabetes, acute kidney injury, and gastrointestinal adverse reactions. Report any new neck lump, hoarseness, difficulty swallowing, or severe abdominal pain radiating to the back to a physician immediately. These warnings apply independently of pregnancy status.
Managing Diabetes and Weight During Pregnancy
Stopping semaglutide raises an immediate practical question: what replaces it? The answer depends entirely on why it was prescribed.
| Original Indication | Approach During Pregnancy | Rationale |
|---|---|---|
| Type 2 diabetes | Insulin. The established first-line therapy for diabetes in pregnancy | Extensive safety record; does not cross the placenta in meaningful quantities; can be titrated rapidly to changing requirements |
| Type 2 diabetes, metformin-treated | Case by case. Continuation is sometimes appropriate under obstetric supervision | Widely used in pregnancy; the decision depends on glycemic control and clinician judgment |
| Weight management | Discontinue. Pharmacotherapy stops; nutritional and activity guidance replaces it | Intentional weight loss is not recommended during pregnancy, even in patients with obesity |
| Cardiovascular risk reduction | Specialist referral. Reassess with the obstetric and cardiology team | The risk-benefit calculus changes fundamentally in pregnancy and requires specialist input |
Weight gain during pregnancy is expected and appropriate. Patients who achieved significant weight loss on semaglutide often find the prospect of regain distressing, and that reaction deserves acknowledgment rather than dismissal. Weight management can resume postpartum under clinical supervision. For a full clinical guide to how supervised semaglutide therapy is structured outside of pregnancy, see our article on semaglutide for weight management: evidence-based dosing, risks and expectations.
Contraception, Fertility, and Unplanned Conception
An unexpected pattern has emerged since GLP-1 receptor agonists entered widespread use: unplanned pregnancies in patients who believed conception was unlikely. There are two plausible mechanisms, and they are not mutually exclusive.
Weight loss can restore ovulation. Obesity and insulin resistance are established contributors to anovulation, particularly in polycystic ovary syndrome. Meaningful weight loss and improved insulin sensitivity can restore regular ovulatory cycles in patients who had irregular or absent periods for years. Fertility returns before the patient has any reason to expect it, and contraceptive vigilance has often lapsed in the interim.
Delayed gastric emptying may affect oral contraceptive absorption. GLP-1 receptor agonists slow gastric emptying. Whether this meaningfully reduces the efficacy of combined oral contraceptives in the case of semaglutide is not firmly established, but the mechanism is plausible and is explicitly addressed in the labeling of some GLP-1 products. Patients relying on oral contraception should raise this with their clinician rather than assume it does not apply.
Semaglutide and Pregnancy: Three Clinical Pathways
Figure 2. Educational summary only. Every pathway requires individual assessment by a licensed clinician.
Any patient of reproductive potential taking semaglutide who does not intend to conceive should use effective contraception for the full duration of treatment and through the washout period. Non-oral methods — intrauterine devices, implants, or barrier methods used alongside oral contraception — remove the gastric emptying question entirely. This is worth discussing at the start of therapy rather than after a surprise. For the equivalent considerations with the other major GLP-1 molecule, see our complete guide to tirzepatide side effects.
Breastfeeding and Restarting After Delivery
Semaglutide is not recommended during breastfeeding. It was present in the milk of lactating rats, and there are no human data on transfer into breast milk, on effects on the breastfed infant, or on milk production. The absence of data is the reason for the recommendation — it is a precaution rather than a documented harm.
Patients who wish to resume therapy after delivery have two practical paths: complete breastfeeding first and restart afterward, or transition to formula feeding if resuming metabolic treatment is the higher clinical priority. Which is appropriate depends on the severity of the metabolic indication and on the patient’s own priorities. This is a conversation to have with a clinician, not a question with a single correct answer.
Restarting is not automatic in any case. Metabolic status frequently changes across pregnancy and the postpartum period, so current labs and clinical assessment should drive the decision rather than the pre-pregnancy prescription. Patients whose therapy involved tirzepatide rather than semaglutide should review the product-specific considerations in our guide on safe use of tirzepatide: dosage, black box warning and telemedicine compliance.
Working With Your Clinician on Timing
The single most useful thing a patient of reproductive potential can do is raise the subject early — ideally when starting therapy, not months into it. A discontinuation timeline planned in advance is straightforward. One improvised after a positive test is not.
Questions worth bringing to the next appointment: What is my target conception date, and what does that mean for my final injection? How will my diabetes be managed during the washout and through pregnancy? What contraception is appropriate while I remain on therapy? If I conceive sooner than planned, what is the first thing I should do?
Get a Physician Evaluation for GLP-1 Therapy
Advanced TRT Clinic provides administrative and technology services that connect patients with independent licensed clinicians through Beluga Health, P.A., who provide all clinical evaluation, treatment selection, prior authorization support, and ongoing monitoring. Clinicians can review your current therapy, reproductive plans, and metabolic status, and can coordinate a discontinuation timeline with your obstetric provider. Advanced TRT Clinic is not a pharmacy, does not fill prescriptions, and is not affiliated with, endorsed by, or a distributor for Novo Nordisk or Eli Lilly. All prescribing decisions are made by independent licensed clinicians based on individual patient assessment. Availability varies by state.
